$RPRX
Royalty Pharma plc Stock $rprx

$rprx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000180276823000007 Filed on February 15, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$565.7M	$2.237B	$575.7M
YoY Change	-1.73%	-2.28%	0.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$73.23M	$227.3M	$46.16M
YoY Change	58.64%	24.33%	-7.86%
% of Gross Profit
Research & Development	$50.50M	$177.1M	$103.8M
YoY Change	-51.36%	-11.49%	1231.04%
% of Gross Profit
Depreciation & Amortization	$0.00	$5.670M	$5.796M
YoY Change	-100.0%	-75.34%	-0.07%
% of Gross Profit
Operating Expenses	$432.6M	$177.1M	$422.3M
YoY Change	2.44%	-11.49%	63.61%
Operating Profit		$307.1M
YoY Change		-78.54%
Interest Expense	-$126.2M	$188.0M	-$94.93M
YoY Change	32.96%	13.13%	-268.31%
% of Operating Profit		61.21%
Other Income/Expense, Net	-$1.165M	-$77.00M	-$4.820M
YoY Change	-75.83%	-59.37%	-401.25%
Pretax Income	-$610.0M	$230.1M	$53.67M
YoY Change	-1236.61%	-81.46%	-85.36%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%	0.0%
Net Earnings	-$456.1M	$42.83M	$7.904M
YoY Change	-5870.29%	-93.09%	-95.38%
Net Earnings / Revenue	-80.62%	1.91%	1.37%
Basic Earnings Per Share		$0.10
Diluted Earnings Per Share	-$1.03	$0.10	$18.32K
COMMON SHARES
Basic Shares Outstanding		438.0M shares
Diluted Shares Outstanding		438.0M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.712B	$2.428B	$1.607B
YoY Change	6.53%	-13.39%	48.99%
Cash & Equivalents	$1.711B	$1.711B	$1.541B
Short-Term Investments	$1.300M	$717.0M	$66.00M
Other Short-Term Assets	$90.52M	$90.52M	$6.631M
YoY Change	1265.1%	1265.1%	-22.86%
Inventory
Prepaid Expenses
Receivables	$16.83M	$16.83M	$53.29M
Other Receivables	$19.77M	$19.77M	$15.02M
Total Short-Term Assets	$2.555B	$2.555B	$2.878B
YoY Change	-11.23%	-11.23%	6.72%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$397.2M	$14.23B	$435.4M
YoY Change	-8.78%	-2.73%	-4.3%
Other Assets	$29.63M	$29.63M	$4.145M
YoY Change	614.81%	614.81%	-58.54%
Total Long-Term Assets	$14.26B	$14.26B	$14.64B
YoY Change	-2.59%	-2.59%	9.86%
TOTAL ASSETS
Total Short-Term Assets	$2.555B	$2.555B	$2.878B
Total Long-Term Assets	$14.26B	$14.26B	$14.64B
Total Assets	$16.81B	$16.81B	$17.52B
YoY Change	-4.01%	-4.01%	9.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.906M	$7.906M	$5.620M
YoY Change	40.68%	40.68%	-48.91%
Accrued Expenses	$54.16M	$54.16M	$57.70M
YoY Change	-6.13%	-6.13%	-62.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$997.5M	$997.5M	$0.00
YoY Change
Total Short-Term Liabilities	$1.167B	$1.167B	$171.3M
YoY Change	581.33%	581.33%	-44.38%
LONG-TERM LIABILITIES
Long-Term Debt	$6.119B	$6.119B	$7.096B
YoY Change	-13.77%	-13.77%	22.0%
Other Long-Term Liabilities	$2.500M	$2.500M	$0.00
YoY Change
Total Long-Term Liabilities	$6.121B	$6.121B	$7.096B
YoY Change	-13.74%	-13.74%	22.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.167B	$1.167B	$171.3M
Total Long-Term Liabilities	$6.121B	$6.121B	$7.096B
Total Liabilities	$7.288B	$11.19B	$7.267B
YoY Change	0.29%	-4.72%	18.66%
SHAREHOLDERS EQUITY
Retained Earnings	$1.965B		$2.255B
YoY Change	-12.88%		17.42%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.806M		$2.715M
YoY Change	3.35%		17.18%
Treasury Stock Shares
Shareholders Equity	$5.628B	$5.628B	$5.777B
YoY Change
Total Liabilities & Shareholders Equity	$16.81B	$16.81B	$17.52B
YoY Change	-4.01%	-4.01%	9.34%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$456.1M	$42.83M	$7.904M
YoY Change	-5870.29%	-93.09%	-95.38%
Depreciation, Depletion And Amortization	$0.00	$5.670M	$5.796M
YoY Change	-100.0%	-75.34%	-0.07%
Cash From Operating Activities	$569.9M	$2.144B	$490.0M
YoY Change	16.32%	6.27%	-13.37%
INVESTING ACTIVITIES
Capital Expenditures	$250.2M	$1.742B	-$171.7M
YoY Change	-245.71%	-179.47%	-78.67%
Acquisitions
YoY Change
Other Investing Activities	$665.0M	$712.2M	-$379.9M
YoY Change	-275.04%	121.72%	1291.62%
Cash From Investing Activities	$414.7M	-$1.029B	-$551.6M
YoY Change	-175.18%	-44.96%	-33.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	-265.5M	-$944.9M	-198.1M
YoY Change	34.07%	-345.35%	-28.6%
NET CHANGE
Cash From Operating Activities	569.9M	$2.144B	490.0M
Cash From Investing Activities	414.7M	-$1.029B	-551.6M
Cash From Financing Activities	-265.5M	-$944.9M	-198.1M
Net Change In Cash	719.1M	$169.7M	-259.8M
YoY Change	-376.84%	-68.12%	-52.27%
FREE CASH FLOW
Cash From Operating Activities	$569.9M	$2.144B	$490.0M
Capital Expenditures	$250.2M	$1.742B	-$171.7M
Free Cash Flow	$319.7M	$402.3M	$661.7M
YoY Change	-51.69%	-90.44%	-51.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001802768
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member
CY2022Q4	us-gaap	Derivative Asset Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Derivative Asset Current Statement Of Financial Position Extensible Enumeration DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherAssetsCurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39329
CY2022	dei	Entity Registrant Name EntityRegistrantName	Royalty Pharma plc
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1535773
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	110 East 59th Street
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
CY2022	dei	City Area Code CityAreaCode	212
CY2022	dei	Local Phone Number LocalPhoneNumber	883-0200
CY2022	dei	Security12b Title Security12bTitle	Class A ordinary shares, par value $0.0001
CY2022	dei	Trading Symbol TradingSymbol	RPRX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	18500000000	usd
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1710751000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1541048000	usd
CY2022Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	24421000	usd
CY2021Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	581872000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	691319000	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	614351000	usd
CY2022Q4	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	16830000	usd
CY2021Q4	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	53286000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1300000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	66000000	usd
CY2022Q4	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	19767000	usd
CY2021Q4	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	15023000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	90520000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6631000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2554908000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2878211000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	13493106000	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	13718245000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5670000	usd
CY2022Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	112348000	usd
CY2021Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	269800000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	226300000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	204400000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	397175000	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	435394000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29629000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4145000	usd
CY2022Q4	us-gaap	Assets Assets	16813466000	usd
CY2021Q4	us-gaap	Assets Assets	17515865000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	94803000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	107934000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7906000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5620000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	54162000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	57696000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	997512000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12400000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1166783000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	171250000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6118810000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7096070000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2500000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7288093000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7267320000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2022Q4	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2022Q4	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	371325000	shares
CY2022Q4	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	371325000	shares
CY2021Q4	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	361170000	shares
CY2021Q4	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	361170000	shares
CY2022Q4	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	usd
CY2021Q4	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3666160000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3507533000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1964689000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2255179000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	3897223000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	4471951000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16491000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2806000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2715000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9525373000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10248545000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16813466000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17515865000	usd
CY2022	us-gaap	Revenues Revenues	2237215000	usd
CY2021	us-gaap	Revenues Revenues	2289463000	usd
CY2020	us-gaap	Revenues Revenues	2122353000	usd
CY2022	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	904244000	usd
CY2021	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	452842000	usd
CY2020	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	230839000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	177106000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	200084000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26289000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5670000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22996000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23058000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	227303000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	182826000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	181715000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	615827000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65053000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	1930150000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	858748000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	526954000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	307065000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1430715000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	1595399000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8973000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-19490000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	44459000	usd
CY2022	us-gaap	Interest Expense InterestExpense	187961000	usd
CY2021	us-gaap	Interest Expense InterestExpense	166142000	usd
CY2020	us-gaap	Interest Expense InterestExpense	157059000	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	96610000	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-21532000	usd
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-42076000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-33442000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-48066000	usd
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	247073000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-6815000	usd
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	17859000	usd
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	18600000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	78335000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	53535000	usd
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	28379000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14755000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5678000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32821000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77001000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-189514000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	106555000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	230064000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1241201000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1701954000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	1701954000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	187232000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	621473000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	726914000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	42832000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	619728000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	975040000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.49
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	437963000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	414794000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	375444000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	437972000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	414802000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	375455000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	1701954000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	0	usd
CY2020	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4066000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24000000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11600000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	83120000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	53432000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50896000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	20551000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-29432000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-39296000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	66635000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	200632000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1201905000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1768589000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	175418000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	604323000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	739787000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25214000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	597582000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1028802000	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6141438000	usd
CY2020	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	1482322000	usd
CY2020	rprx	Noncontrolling Interest Transfers Of Interests NoncontrollingInterestTransfersOfInterests	0	usd
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1105765000	usd
CY2020	rprx	Stock Issued During Period Value Issued For Registration StockIssuedDuringPeriodValueIssuedForRegistration	63000	usd
	us-gaap	Profit Loss ProfitLoss	624885000	usd
CY2020	rprx	Stock Issued During Period Value Issued To Partnerships StockIssuedDuringPeriodValueIssuedToPartnerships	1000	usd
CY2020	rprx	Stockholders Equity Value Effect Of Exchange And Reallocation StockholdersEquityValueEffectOfExchangeAndReallocation	-1000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1908744000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5428000	usd
CY2020	us-gaap	Stockholders Equity Other StockholdersEquityOther	-191000	usd
CY2020	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2020	us-gaap	Dividends Cash DividendsCash	112490000	usd
	us-gaap	Profit Loss ProfitLoss	1077069000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4066000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	83120000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	20551000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9895815000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9895815000	usd
CY2021	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	48539000	usd
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	614973000	usd
CY2021	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.68
CY2021	us-gaap	Dividends Cash DividendsCash	285184000	usd
CY2021	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2443000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11600000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50896000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10248545000	usd
CY2022	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	11596000	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	604248000	usd
CY2022	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.76
CY2022	us-gaap	Dividends Cash DividendsCash	333322000	usd
CY2022	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2170000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	53432000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9525373000	usd
CY2022	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	2507236000	usd
CY2021	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	2315854000	usd
CY2020	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	2121923000	usd
CY2022	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	72943000	usd
CY2021	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	151158000	usd
CY2020	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	143753000	usd
CY2022	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	69891000	usd
CY2021	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	44123000	usd
CY2020	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	18305000	usd
CY2022	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	39142000	usd
CY2021	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	34384000	usd
CY2020	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	42334000	usd
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	24982000	usd
CY2021	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	3135000	usd
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	7704000	usd
CY2022	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	0	usd
CY2021	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	34660000	usd
CY2020	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	45252000	usd
CY2022	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	0	usd
CY2021	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	34660000	usd
CY2020	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	0	usd
CY2022	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	0	usd
CY2021	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	16093000	usd
CY2020	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	35448000	usd
CY2022	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	2106000	usd
CY2021	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	6876000	usd
CY2020	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	20479000	usd
CY2022	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	175000000	usd
CY2021	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	193208000	usd
CY2020	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	5810000	usd
CY2022	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	222969000	usd
CY2021	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	184511000	usd
CY2020	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	179709000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	170139000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	130430000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	103196000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2143980000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2017536000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2034629000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	62500000	usd
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3000000	usd
CY2022	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
CY2021	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	523000	usd
CY2020	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	15084000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	9896000	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	34855000	usd
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	40155000	usd
CY2022	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	87785000	usd
CY2021	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	135134000	usd
CY2020	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	50000000	usd
CY2022	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	211158000	usd
CY2021	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	115957000	usd
CY2020	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	384840000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	479559000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	70441000	usd
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	542044000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	234869000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1196579000	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1705283000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	792341000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1597851000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	815440000	usd
CY2022	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	1741640000	usd
CY2021	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	2191502000	usd
CY2020	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	2182246000	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	21215000	usd
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2020	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2022	rprx	Payments For Milestones PaymentsForMilestones	0	usd
CY2021	rprx	Payments For Milestones PaymentsForMilestones	18600000	usd
CY2020	rprx	Payments For Milestones PaymentsForMilestones	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1029421000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1870280000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2759320000	usd
CY2022	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	0	usd
CY2021	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	0	usd
CY2020	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	285353000	usd
CY2022	rprx	Payments To Noncontrolling Interests Royalty Receipts PaymentsToNoncontrollingInterestsRoyaltyReceipts	441963000	usd
CY2021	rprx	Payments To Noncontrolling Interests Royalty Receipts PaymentsToNoncontrollingInterestsRoyaltyReceipts	479604000	usd
CY2020	rprx	Payments To Noncontrolling Interests Royalty Receipts PaymentsToNoncontrollingInterestsRoyaltyReceipts	543952000	usd
CY2022	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	31301000	usd
CY2021	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	20367000	usd
CY2020	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	67654000	usd
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	144115000	usd
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	133433000	usd
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	113481000	usd
CY2022	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	333322000	usd
CY2021	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	285184000	usd
CY2020	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	112490000	usd
CY2022	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	1059000	usd
CY2021	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	7339000	usd
CY2020	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	8482000	usd
CY2022	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	6133000	usd
CY2021	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	36874000	usd
CY2020	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	58957000	usd
CY2022	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	0	usd
CY2021	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	0	usd
CY2020	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	94200000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11116196000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1272533000	usd
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11891030000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1347000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13046000	usd
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	46715000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1908744000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-944856000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	385112000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1487172000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	169703000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	532368000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	762481000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1541048000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1008680000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246199000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1710751000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1541048000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1008680000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	The COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.
CY2022Q4	rprx	Number Of Noncontrolling Interests Created NumberOfNoncontrollingInterestsCreated	4	noncontrolling_interest
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Certain prior period amounts have been reclassified to conform to the current period presentation.
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of December 31, 2022 and 2021 were held with State Street</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bank of America, US Bank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Scotiabank</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co, Pfizer, Astellas, Novartis, and Gilead. As of December 31, 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 31% and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div>
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q4	rprx	Common Stock Exchange Ratio CommonStockExchangeRatio	1
CY2022Q1	rprx	Long Term Funding Partnership Amount LongTermFundingPartnershipAmount	300000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Number Of Tranches LongTermFundingPartnershipNumberOfTranches	5	tranche
CY2022Q1	rprx	Long Term Funding Partnership Initial Payment LongTermFundingPartnershipInitialPayment	50000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Covenant Required Amount LongTermFundingPartnershipCovenantRequiredAmount	50000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Additional Payments Aggregate Amount LongTermFundingPartnershipAdditionalPaymentsAggregateAmount	200000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Interest Free And Payment Free Period Number Of Calendar Quarters Tranche One LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne	6	tranche
CY2022Q1	rprx	Long Term Funding Partnership Interest Free And Payment Free Period Number Of Calendar Quarters Tranche Two LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo	34	tranche
CY2022Q1	rprx	Long Term Funding Partnership Installment Repayments Amount Drawn Multiple LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple	1.9
CY2022Q1	rprx	Long Term Funding Partnership Total Amount Drawn LongTermFundingPartnershipTotalAmountDrawn	2.0
CY2022	rprx	Long Term Funding Partnership Expected Payment LongTermFundingPartnershipExpectedPayment	125000000	usd
CY2022	rprx	Long Term Funding Partnership Additional Payments Aggregate Amount LongTermFundingPartnershipAdditionalPaymentsAggregateAmount	200000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	53400000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50900000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	20600000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	350000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	124900000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225100000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1300000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	226300000	usd
CY2022Q4	rprx	Debt Securities Available For Sale Liability Current DebtSecuritiesAvailableForSaleLiabilityCurrent	0	usd
CY2022Q4	rprx	Debt Securities Available For Sale Liability Noncurrent DebtSecuritiesAvailableForSaleLiabilityNoncurrent	-2500000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225100000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	204509000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	65891000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	270400000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	66000000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	204400000	usd
CY2021Q4	rprx	Debt Securities Available For Sale Liability Current DebtSecuritiesAvailableForSaleLiabilityCurrent	0	usd
CY2021Q4	rprx	Debt Securities Available For Sale Liability Noncurrent DebtSecuritiesAvailableForSaleLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	270400000	usd
CY2021Q2	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	600000000	usd
CY2020Q1	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	35400000	usd
CY2020Q1	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	45300000	usd
CY2022	rprx	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	fair value
CY2021	rprx	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	fair value
CY2022	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	39100000	usd
CY2021	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	41400000	usd
CY2020	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	0	usd
CY2022	rprx	Debt Securities Available For Sale Restriction Period DebtSecuritiesAvailableForSaleRestrictionPeriod	P6M
CY2022Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	16776307000	usd
CY2022Q4	rprx	Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows	2476460000	usd
CY2022Q4	rprx	Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows	14299847000	usd
CY2022Q4	rprx	Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal	115422000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	14184425000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	14200000000	usd
CY2022Q4	rprx	Unapproved Financial Assets Held At Costs UnapprovedFinancialAssetsHeldAtCosts	533800000	usd
CY2021Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	16027541000	usd
CY2021Q4	rprx	Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows	1384141000	usd
CY2021Q4	rprx	Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows	14643400000	usd
CY2021Q4	rprx	Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal	310804000	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	14332596000	usd
CY2019Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	868418000	usd
CY2020	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	645612000	usd
CY2020	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	570959000	usd
CY2020	rprx	Financing Receivable Change In Present Value Write Off Cumulative Allowance FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance	2964000	usd
CY2020	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	25174000	usd
CY2020	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	156186000	usd
CY2020Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	1263824000	usd
CY2021	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	912710000	usd
CY2021	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	446955000	usd
CY2021	rprx	Financing Receivable Change In Present Value Write Off Cumulative Allowance FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance	21721000	usd
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-12913000	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	1694945000	usd
CY2022	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	1394679000	usd
CY2022	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	296637000	usd
CY2022	rprx	Financing Receivable Change In Present Value Write Off Cumulative Allowance FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance	5723000	usd
CY2022	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	1584000	usd
CY2022	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-193798000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	2591882000	usd
CY2020	rprx	Financing Receivable Allowance For Credit Loss Financial Royalty Asset Writeoff FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff	90200000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	606216000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	600546000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5670000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	177100000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	200100000	usd
CY2021	rprx	Research And Development Expense Upfront Payment And Premium Paid ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid	193200000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26300000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	183678000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	203930000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	7116322000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	7096070000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	997512000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6118810000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7096070000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	183700000	usd
CY2022Q4	rprx	Number Of Classes Of Voting Stock NumberOfClassesOfVotingStock	2	class
CY2022Q4	rprx	Common Stock Voting Rights Number Of Votes CommonStockVotingRightsNumberOfVotes	1	vote
CY2022Q4	rprx	Common Stock Quarterly Conversion Basis CommonStockQuarterlyConversionBasis	1	shares
CY2021Q4	rprx	Number Of Noncontrolling Interests NumberOfNoncontrollingInterests	4	noncontrolling_interest
CY2022Q4	rprx	Number Of Noncontrolling Interests NumberOfNoncontrollingInterests	4	noncontrolling_interest
CY2020Q4	rprx	Number Of Noncontrolling Interests NumberOfNoncontrollingInterests	4	noncontrolling_interest
CY2022Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.19
CY2022Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.19
CY2022Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.19
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.19
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	333300000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P1Y
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	42832000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	42832000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	619728000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	619728000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	437963000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	414794000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	437972000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	414802000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.49
CY2020	us-gaap	Profit Loss ProfitLoss	1701954000	usd
CY2020	rprx	Net Income Loss Attributable To Parent Prior To Offering NetIncomeLossAttributableToParentPriorToOffering	479842000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	495198000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	495198000	usd
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	375444000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	11000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	375455000	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	1701954000	usd
CY2022	rprx	Increase Decrease In Financial Royalty Assets IncreaseDecreaseInFinancialRoyaltyAssets	2125096000	usd
CY2021	rprx	Increase Decrease In Financial Royalty Assets IncreaseDecreaseInFinancialRoyaltyAssets	2065083000	usd
CY2020	rprx	Increase Decrease In Financial Royalty Assets IncreaseDecreaseInFinancialRoyaltyAssets	1959975000	usd
CY2022	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	904244000	usd
CY2021	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	452842000	usd
CY2020	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	230839000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5670000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22996000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23058000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21356000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	20162000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11715000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	96610000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-21532000	usd
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-42076000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-33442000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-48066000	usd
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	247073000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8973000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-19490000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	44459000	usd
CY2022	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	39142000	usd
CY2021	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	34384000	usd
CY2020	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	42334000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-358000	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30272000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2170000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2443000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5428000	usd
CY2022	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	53432000	usd
CY2021	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	50896000	usd
CY2020	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	20551000	usd
CY2022	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-6815000	usd
CY2021	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	17859000	usd
CY2020	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	18600000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	615827000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65053000	usd
CY2022	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	0	usd
CY2021	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	16093000	usd
CY2020	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	34952000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-11098000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4461000	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-9621000	usd
CY2022	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	2507236000	usd
CY2021	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	2315854000	usd
CY2020	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	2121923000	usd
CY2022	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-36456000	usd
CY2021	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	20131000	usd
CY2020	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-370000	usd
CY2022	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	4744000	usd
CY2021	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	9012000	usd
CY2020	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	770000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2198000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1857000	usd
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-34986000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2286000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4586000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-766000	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-3534000	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	15550000	usd
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	42146000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2143980000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2017536000	usd
CY2020	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	110000000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2034629000	usd
CY2022	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	0	usd
CY2021	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	0	usd
CY2020	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	303679000	usd
CY2022	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	0	usd
CY2021	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	0	usd
CY2020	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	5700000	usd
CY2022	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	0	usd
CY2021	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	0	usd
CY2020	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	110000000	usd
CY2022	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	0	usd
CY2021	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	0	usd
CY2020	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	1103774000	usd
CY2022	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	12400000	usd
CY2021	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	0	usd
CY2020	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	18600000	usd
CY2022Q4	rprx	Long Term Funding Commitment Amount Outstanding LongTermFundingCommitmentAmountOutstanding	250000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Covenant Required Amount LongTermFundingPartnershipCovenantRequiredAmount	50000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Additional Payments Aggregate Amount LongTermFundingPartnershipAdditionalPaymentsAggregateAmount	200000000	usd
CY2022	rprx	Long Term Funding Partnership Expected Payment LongTermFundingPartnershipExpectedPayment	125000000	usd
CY2022	rprx	Long Term Funding Partnership Additional Payments Aggregate Amount LongTermFundingPartnershipAdditionalPaymentsAggregateAmount	200000000	usd
CY2022Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	94803000	usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	107934000	usd

Files In Submission

Name	View Source	Status
0001802768-23-000007-index-headers.html	Edgar Link	pending
0001802768-23-000007-index.html	Edgar Link	pending
0001802768-23-000007.txt	Edgar Link	pending
0001802768-23-000007-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rprx-20221231.htm	Edgar Link	pending
rprx-20221231.xsd	Edgar Link	pending
rprx-20221231ex211.htm	Edgar Link	pending
rprx-20221231ex231.htm	Edgar Link	pending
rprx-20221231ex311.htm	Edgar Link	pending
rprx-20221231ex312.htm	Edgar Link	pending
rprx-20221231ex32.htm	Edgar Link	pending
rprx-20221231ex42.htm	Edgar Link	pending
rprx-20221231_g1.jpg	Edgar Link	pending
rprx-20221231_g2.jpg	Edgar Link	pending
rprx-20221231_g3.jpg	Edgar Link	pending
rprx-20221231_g4.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
rprx-20221231_cal.xml	Edgar Link	unprocessable
rprx-20221231_def.xml	Edgar Link	unprocessable
rprx-20221231_pre.xml	Edgar Link	unprocessable
rprx-20221231_lab.xml	Edgar Link	unprocessable
rprx-20221231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RPRX
Royalty Pharma plc Stock $rprx

2022 Q4 Form 10-K Financial Statement

#000180276823000007 Filed on February 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX Royalty Pharma plc Stock $rprx

2022 Q4 Form 10-K Financial Statement

#000180276823000007 Filed on February 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX
Royalty Pharma plc Stock $rprx